ir.fusionpharma.comInvestors | Fusion Pharmaceuticals - Overview
ir.fusionpharma.com Profile
Ir.fusionpharma.com is a subdomain of fusionpharma.com, which was created on 2006-03-18,making it 18 years ago.
Discover ir.fusionpharma.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.fusionpharma.com Information
| HomePage size: 257.212 KB |
| Page Load Time: 0.779204 Seconds |
| Website IP Address: 104.17.204.159 |
ir.fusionpharma.com Similar Website
| Maryland Real Estate Investors Association - Maryland Real Estate Investors Association |
| Western Midstream - Investors - Investors |
| OMNOVA Solutions - Investors - Investors |
| Investors :: Conatus Pharmaceuticals Inc. (CNAT) |
| Ironwood Pharmaceuticals, Inc. - Company Overview |
| Investors | Marathon Oil Corporation - Investors |
| Axalta Coating Systems - Investors - Investors Overview |
| SAP Concur Fusion 2024 - Register now - SAP Concur Fusion |
| Investors & Media | Ionis Pharmaceuticals, Inc. |
| Fusion Helpdesk - Fusion HelpDesk |
| Momenta Pharmaceuticals, Inc. - News/Events - Overview |
| Inovio Pharmaceuticals, Inc. - INVESTORS & MEDIA |
| Investors | Syndax Pharmaceuticals, Inc. |
| Overview | Cyclacel Pharmaceuticals, Inc. |
| Lifeline Pharmaceuticals, LLC’s Login Page | Lifeline Pharmaceuticals, LLC |
ir.fusionpharma.com PopUrls
| Investors | Fusion Pharmaceuticals - Overview https://ir.fusionpharma.com/ |
| Financial Snapshot https://ir.fusionpharma.com/financial-snapshot |
| SEC Filings https://ir.fusionpharma.com/sec-filings |
| RSS https://ir.fusionpharma.com/rss |
| Investors | Fusion Pharmaceuticals - Management https://ir.fusionpharma.com/management |
| Board Committees https://ir.fusionpharma.com/board-committees |
| Events & Presentations https://ir.fusionpharma.com/events-webcasts |
| philina lee, ph.d. https://ir.fusionpharma.com/philina-lee |
| Key Ratios https://ir.fusionpharma.com/key-ratios |
| Investors | Fusion Pharmaceuticals - Interactive Chart https://ir.fusionpharma.com/interactive-chart |
| Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 ... https://ir.fusionpharma.com/2024-05-09-Fusion-Pharmaceuticals-Announces-First-Patient-Dosed-in-the-Phase-2-Portion-of-the-AlphaBreak-Trial-Evaluating- |
ir.fusionpharma.com Httpheader
| Date: Tue, 14 May 2024 00:59:45 GMT |
| Content-Type: text/html; charset=UTF-8 |
| Transfer-Encoding: chunked |
| Connection: keep-alive |
| X-Frame-Options: SAMEORIGIN |
| Strict-Transport-Security: max-age=31536000; includeSubDomains |
| Cache-Control: public, no-cache |
| Vary: Accept-Encoding |
| CF-Cache-Status: EXPIRED |
| Last-Modified: Mon, 13 May 2024 12:46:11 GMT |
| Server: cloudflare |
| CF-RAY: 8836f2852bf17bcd-LAX |
ir.fusionpharma.com Meta Info
| content="text/html; charset=utf-8" http-equiv="Content-Type"/ |
| content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0" name="viewport"/ |
| content="" name="keywords" |
| content="" name="description" |
| content="summary" name="twitter:card"/ |
| content="Investors | Fusion Pharmaceuticals" property="og:site_name"/ |
| content="https://ir.fusionpharma.com/overview" property="og:url"/ |
| content="WordPress 5.4.1" name="generator"/ |
| content="WooCommerce 3.8.1" name="generator"/ |
| content="Powered by WPBakery Page Builder - drag and drop page builder for WordPress." name="generator"/ |
| content="https://fusionpharma.com/wp-content/uploads/2018/11/cropped-logo-dark-270x270.png" name="msapplication-TileImage"/ |
ir.fusionpharma.com Html To Plain Text
About Fusion Management Board Of Directors Advisory Board Contact Pipeline Technology Investors & Media Overview News Releases Stock Information Corporate Governance Financial Information SEC Filings Analyst Coverage Events & Presentations Investor Resources Careers Investor Relations Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear™ linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the therapies to tumors. We believe our proprietary Fast-Clear™ linker technology is a safer approach to targeted radiopharmaceuticals. Fast-Clear™ represents a revolutionary step towards developing safe and effective new radiotherapeutics as the standard of care for the treatment of multiple tumor types. We believe this evolution of radiopharmaceuticals holds great promise to improve the lives of patients with cancer.Recent News Email Alerts May 09 Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastatic castration-resistant prostate cancer HAMILTON, ON and BOSTON, May 9, 2024 /PRNewswire/Fusion... May 07 Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates Presented interim data from TATCIST trial of FPI-2265 in mCRPC at the 2024 American Association for Cancer Research (AACR) Annual Meeting Signed definitive agreement to be acquired by AstraZeneca... Apr 25 Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that it has filed... View All Overview Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus fermentum urna dictum sem sollicitudin fringilla. Donec porttitor tristique congue. Vestibulum congue cursus nunc, at convallis augue pulvinar sit amet. Maecenas interdum rhoncus ullamcorper. Aliquam maximus purus in sapien bibendum, ac pulvinar ipsum venenatis. Praesent maximus sapien rhoncus massa tincidunt pretium. Vivamus ornare sem vitae purus efficitur luctus. Maecenas feugiat a lorem sit amet dignissim. Vestibulum varius tincidunt lobortis. Nulla maximus, nisi vitae tempus gravida, urna metus placerat diam, luctus mollis justo augue vel enim. Mauris condimentum convallis diam, eget sodales enim egestas sollicitudin. Donec vitae maximus risus, et euismod risus. Aliquam erat volutpat. Phasellus ultricies ac turpis nec dignissim. In auctor augue massa, vulputate ullamcorper ipsum ultricies non. Stock Information NASDAQ FUSN NEVER MISS AN UPDATE SIGN UP FOR INVESTOR ALERTS info@fusionpharma.com Toll free +1 (888) 506-4125 Home About Pipeline Technology Investors Careers Contact CANADA 270 Longwood Road South Hamilton, ON, L8P 0A6 (289) 799-0891 UNITED STATES 2 International Place, Suite 2310 Boston, MA 02110 (617) 420-5698 © 2020 Fusion Pharma. All Rights Reserved About About Fusion Management Board Of Directors Advisory Board Contact Pipeline Technology Investors Overview News Releases Stock Information Corporate Governance Financial Information SEC Filings Analyst Coverage Events & Presentations Investor Resources Careers x Learn more about investor resources Your Name (required) Your Email (required) Subject Your Message CLOSE Learn more about Fusion & our Investigational Trials Your Name (required) Your Email (required) Subject Your Message CLOSE Learn more about Fusion & Investigational Trials For general inquiries, please use the contact form or email Name Email Who are you? Investor Healthcare Professional Patient Investor Healthcare Professional Patient Subject Message...
ir.fusionpharma.com Whois
Domain Name: FUSIONPHARMA.COM Registry Domain ID: 379796779_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.webnames.ca Registrar URL: http://www.webnames.ca Updated Date: 2024-04-11T15:02:35Z Creation Date: 2006-03-18T01:54:29Z Registry Expiry Date: 2025-03-18T00:54:29Z Registrar: Webnames.ca Inc. Registrar IANA ID: 456 Registrar Abuse Contact Email: abuse@webnames.ca Registrar Abuse Contact Phone: 18662217878 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS1.WEBNAMES.CA Name Server: NS2.WEBNAMES.CA Name Server: NS3.WEBNAMES.CA DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T22:16:05Z <<<